Lv2
150 积分 2025-04-14 加入
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
8小时前
待确认
Tremelimumab: First Approval
7天前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
1个月前
已完结
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Biliary Tract Cancers
3个月前
已完结
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
4个月前
已完结
Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
5个月前
已完结
Safety and Efficacy of Felzartamab in Primary Membranous Nephropathy (PMN): Final Analysis of the M-PLACE Study
5个月前
已关闭
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
